Sarepta Therapeutics
Price & Volume
Stats
See more52W Range | $10.41-$144.22 |
Market Cap | $1.9B |
Shares Short | 20M |
Financials
See moreRevenue (12 Mos) | $2.4B |
Revenue Growth (YoY) | 68.4% |
Gross Profit (12 Mos) | $565.1M |
Diluted EPS | -$0.68 |
News
See moreYahoo Finance • 15 hours ago
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Yahoo Finance • 20 hours ago
Sarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens Berman
Yahoo Finance • 23 hours ago
SRPT FRAUD REMINDER: Sarepta Therapeutics, Inc. Stock Drop Triggers Securities Fraud Class Action – Contact BFA Law before Imminent August 25 Deadline (NASDAQ:SRPT)
Yahoo Finance • yesterday
Sarepta Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline
About
CEO | Mr. Douglas S. Ingram Esq., J.D. |
CFO | Ryan H. Wong |
Address | 215 First Street, Cambridge, MA, United States, 02142 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 1,372 |
